{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-030568","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-08-03T11:41:33+00:00","discovered_at":"2026-08-03T11:45:00.424000+00:00","generated_at":"2026-08-03T11:45:05.274184+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rocket Pharma reports positive safety data from first 3 patients in Phase 2 Danon disease trial","bullets":["Initial three patients treated safely with RP-A501 at recalibrated dose 3.8×10^13 GC/kg; no TMA or capillary leak syndrome observed.","Company engaging with FDA to align on path to complete pivotal Phase 2 trial; regulatory update expected H2 2026.","Comprehensive Danon disease program update on track for H2 2026.","Phase 2 trial designed as 12-patient single-arm study."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-030568","json":"https://secwatch.observer/filing/0001140361-26-030568.json","markdown":"https://secwatch.observer/filing/0001140361-26-030568.md","text":"https://secwatch.observer/filing/0001140361-26-030568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/0001140361-26-030568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/ef20079241_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:45:05.274184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}